
Arie Pieter Kappetein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8878092/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	2.2	4,141
2	Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. New England Journal of Medicine, 2009, 360, 961-972.	27.0	3,634
3	Guidelines on the management of valvular heart disease (version 2012). European Heart Journal, 2012, 33, 2451-2496.	2.2	3,465
4	2014 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2014, 46, 517-592.	1.4	2,164
5	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). European Journal of Cardio-thoracic Surgery, 2012, 42, S45-S60.	1.4	1,605
6	Updated Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2012, 60, 1438-1454.	2.8	1,560
7	Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet, The, 2013, 381, 629-638.	13.7	1,490
8	The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention, 2005, 1, 219-27.	3.2	1,349
9	Guidelines on the management of valvular heart disease (version 2012). European Journal of Cardio-thoracic Surgery, 2012, 42, S1-S44.	1.4	1,313
10	Aortic Stenosis in the Elderly. Journal of the American College of Cardiology, 2013, 62, 1002-1012.	2.8	935
11	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus documentâ€. European Heart Journal, 2012, 33, 2403-2418.	2.2	900
12	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. New England Journal of Medicine, 2016, 375, 2223-2235.	27.0	843
13	Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 6-23.	0.8	783
14	Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical Trials. Journal of the American College of Cardiology, 2011, 57, 253-269.	2.8	735
15	Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. European Heart Journal, 2011, 32, 205-217.	2.2	719
16	2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2012, 59, 1200-1254.	2.8	706
17	Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet, The, 2013, 381, 639-650.	13.7	679
18	Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal, 2008, 29, 1463-1470.	2.2	656

#	Article	IF	CITATIONS
19	Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial. Circulation, 2010, 121, 2645-2653.	1.6	561
20	Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. New England Journal of Medicine, 2019, 381, 1820-1830.	27.0	523
21	Clinical Outcomes After Transcatheter Aortic Valve Replacement Using Valve Academic Research Consortium Definitions. Journal of the American College of Cardiology, 2012, 59, 2317-2326.	2.8	517
22	Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. European Heart Journal, 2011, 32, 2125-2134.	2.2	506
23	Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet, The, 2018, 391, 939-948.	13.7	506
24	Assessment of the SYNTAX score in the Syntax study. EuroIntervention, 2009, 5, 50-56.	3.2	480
25	Five-Year Outcomes in Patients With Left Main Disease Treated With Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Trial. Circulation, 2014, 129, 2388-2394.	1.6	440
26	Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation, 2018, 137, 2635-2650.	1.6	435
27	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: PartÂ2: Endpoint Definitions. Journal of the American College of Cardiology, 2015, 66, 308-321.	2.8	413
28	The impact of prosthesis–patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27 186 patients with 133 141 patient-years. European Heart Journal, 2012, 33, 1518-1529.	2.2	410
29	Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet, The, 2019, 394, 1325-1334.	13.7	406
30	Paravalvular Leak After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2013, 61, 1125-1136.	2.8	374
31	Standardized Definition of Structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves. Circulation, 2018, 137, 388-399.	1.6	350
32	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery	2.2	335
33	(EACTS). European Heart Journal, 2017, 38, 3382-3390. Quantification of Incomplete Revascularization and its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial Validation of the Residual SYNTAX Score. Circulation, 2013, 128, 141-151.	1.6	326
34	Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trialâ€. European Journal of Cardio-thoracic Surgery, 2013, 43, 1006-1013.	1.4	317
35	Short- and Long-Term Clinical Outcome After Drug-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease. Circulation, 2005, 111, 1383-1389.	1.6	305
36	Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. European Heart Journal, 2014, 35, 2821-2830.	2.2	292

#	Article	IF	CITATIONS
37	Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ, The, 2014, 348, g3859-g3859.	6.0	291
38	The Society of Thoracic Surgeons Clinical Practice Guidelines on Arterial Conduits for Coronary Artery Bypass Grafting. Annals of Thoracic Surgery, 2016, 101, 801-809.	1.3	290
39	The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: Design, rationale, and run-in phase. American Heart Journal, 2006, 151, 1194-1204.	2.7	281
40	Diabetic and Nondiabetic Patients With Left Main and/or 3-Vessel Coronary Artery Disease. Journal of the American College of Cardiology, 2010, 55, 1067-1075.	2.8	271
41	Cyphering the Complexity of Coronary Artery Disease Using the Syntax Score to Predict Clinical Outcome in Patients With Three-Vessel Lumen Obstruction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2007, 99, 1072-1081.	1.6	269
42	The Negative Impact of Incomplete Angiographic Revascularization on Clinical Outcomes and Its Association With Total Occlusions. Journal of the American College of Cardiology, 2013, 61, 282-294.	2.8	257
43	Meta-Analysis of Positron Emission Tomographic and Computed Tomographic Imaging in Detecting Mediastinal Lymph Node Metastases in Nonsmall Cell Lung Cancer. Annals of Thoracic Surgery, 2005, 79, 375-382.	1.3	255
44	Mechanical versus bioprosthetic aortic valve replacement. European Heart Journal, 2017, 38, 2183-2191.	2.2	248
45	Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. European Heart Journal, 2017, 38, 3124-3134.	2.2	244
46	Quality of Life after PCI with Drug-Eluting Stents or Coronary-Artery Bypass Surgery. New England Journal of Medicine, 2011, 364, 1016-1026.	27.0	242
47	Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. European Heart Journal, 2018, 39, 2635-2642.	2.2	234
48	Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Journal of Cardio-thoracic Surgery, 2008, 34, 1-8.	1.4	217
49	Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. European Journal of Cardio-thoracic Surgery, 2005, 28, 759-762.	1.4	207
50	Transcatheter Aortic Valve Replacement in Europe. Journal of the American College of Cardiology, 2013, 62, 210-219.	2.8	199
51	A 3-Center Comparison of 1-Year Mortality Outcomes Between Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement on the Basis of Propensity Score Matching Among Intermediate-Risk Surgical Patients. JACC: Cardiovascular Interventions, 2013, 6, 443-451.	2.9	197
52	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: PartÂ1: Clinical Trial Design Principles. Journal of the American College of Cardiology, 2015, 66, 278-307.	2.8	191
53	Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data. European Journal of Cardio-thoracic Surgery, 2012, 41, 535-541.	1.4	182
54	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document#. EuroIntervention, 2012, 8, 782-795.	3.2	182

#	Article	IF	CITATIONS
55	Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease.â~†Insights from the SYNTAX run-in phase. European Journal of Cardio-thoracic Surgery, 2006, 29, 486-491.	1.4	181
56	The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease. European Heart Journal, 2013, 34, 2510-2518.	2.2	167
57	Optimal Medical Therapy Improves Clinical Outcomes in Patients Undergoing Revascularization With Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting. Circulation, 2015, 131, 1269-1277.	1.6	167
58	A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dablGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN). American Heart Journal, 2012, 163, 931-937.e1.	2.7	164
59	Incidence and Predictors of Debris Embolizing to the Brain During Transcatheter Aortic Valve Implantation. JACC: Cardiovascular Interventions, 2015, 8, 718-724.	2.9	161
60	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery	1.4	160
61	(EACTS). European Journal of Cardio-thoracic Surgery, 2017, 52, 408-417. Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: Weighing lifetime anticoagulant-related event risk against reoperation risk. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 881-886.e5.	0.8	156
62	ESC Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in patients with valvular heart disease. European Heart Journal, 2012, 33, 822-828.	2.2	152
63	Relationship between the logistic EuroSCORE and the Society of Thoracic Surgeons Predicted Risk of Mortality score in patients implanted with the CoreValve ReValving System—A Bern-Rotterdam Study. American Heart Journal, 2010, 159, 323-329.	2.7	149
64	Rationale and design of the Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure (TAVR UNLOAD) trial. American Heart Journal, 2016, 182, 80-88.	2.7	142
65	Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. European Heart Journal, 2012, 33, 3098-3104.	2.2	138
66	Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EuroIntervention, 2008, 4, 193-199.	3.2	134
67	Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions. European Heart Journal, 2015, 36, 1878-1891.	2.2	133
68	Preoperative and operative predictors of delirium after cardiac surgery in elderly patients. European Journal of Cardio-thoracic Surgery, 2012, 41, 544-549.	1.4	127
69	Non-inferiority study design: lessons to be learned from cardiovascular trials. European Heart Journal, 2012, 33, 1318-1324.	2.2	126
70	Transcatheter aortic valve implantation 10-year anniversary: review of current evidence and clinical implications. European Heart Journal, 2012, 33, 2388-2398.	2.2	125
71	Complex coronary anatomy in coronary artery bypass graft surgery: Impact of complex coronary anatomy in modern bypass surgery? Lessons learned from the SYNTAX trial after two years. Journal of Thoracic and Cardiovascular Surgery, 2011, 141, 130-140.	0.8	124
72	Coronary artery bypass grafting: Part 1–the evolution over the first 50 years. European Heart Journal, 2013, 34, 2862-2872.	2.2	120

#	Article	IF	CITATIONS
73	Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation. Lancet, The, 2020, 396, 1399-1412.	13.7	120
74	Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) trial. European Heart Journal, 2012, 33, 3105-3113.	2.2	119
75	Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet, The, 2021, 398, 2247-2257.	13.7	115
76	Causes of Death Following PCI Versus CABG in Complex CAD. Journal of the American College of Cardiology, 2016, 67, 42-55.	2.8	110
77	Lung resection for non–small-cell lung cancer in patients older than 70: mortality, morbidity, and late survival compared with the general population. Annals of Thoracic Surgery, 2003, 76, 1796-1801.	1.3	109
78	2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, e29-e84.	0.8	107
79	Short-term mechanical circulatory support as a bridge to durable left ventricular assist device implantation in refractory cardiogenic shock: a systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery, 2017, 52, 14-25.	1.4	106
80	Complete Revascularization Is NotÂa Prerequisite for Success in Current Transcatheter Aortic Valve ImplantationÂPractice. JACC: Cardiovascular Interventions, 2013, 6, 867-875.	2.9	105
81	Coronary artery bypass grafting: Part 2optimizing outcomes and future prospects. European Heart Journal, 2013, 34, 2873-2886.	2.2	103
82	Smoking Is Associated With Adverse Clinical Outcomes in PatientsÂUndergoing Revascularization With PCI or CABG. Journal of the American College of Cardiology, 2015, 65, 1107-1115.	2.8	99
83	Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II. European Heart Journal, 2015, 36, 1231-1241.	2.2	98
84	Costs of Transcatheter Versus Surgical Aortic Valve Replacement in Intermediate-Risk Patients. Annals of Thoracic Surgery, 2012, 94, 1954-1960.	1.3	94
85	New-Onset Atrial Fibrillation After PCIÂorÂCABGÂforÂLeft Main Disease. Journal of the American College of Cardiology, 2018, 71, 739-748.	2.8	94
86	Performance of EuroSCORE II in a large US database: implications for transcatheter aortic valve implantation. European Journal of Cardio-thoracic Surgery, 2014, 46, 400-408.	1.4	93
87	Compliance With Guideline-Directed Medical Therapy in Contemporary CoronaryÂRevascularization Trials. Journal of the American College of Cardiology, 2018, 71, 591-602.	2.8	92
88	A Global Risk Approach to Identify Patients With Left Main or 3-Vessel Disease Who Could Safely and Efficaciously Be Treated With Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 606-617.	2.9	91
89	Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization. Journal of the American College of Cardiology, 2018, 72, 386-398.	2.8	89
90	Bypass Versus Drug-Eluting Stents at Three Years in SYNTAX Patients With Diabetes Mellitus or Metabolic Syndrome. Annals of Thoracic Surgery, 2011, 92, 2140-2146.	1.3	84

#	Article	IF	CITATIONS
91	Cost-Effectiveness of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Bypass Surgery for Patients With 3-Vessel or Left Main Coronary Artery Disease. Circulation, 2014, 130, 1146-1157.	1.6	83
92	Standards defining a â€~Heart Valve Centre': ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint. European Heart Journal, 2017, 38, 2177-2183.	2.2	83
93	Current concepts on coronary revascularization in diabetic patients. European Heart Journal, 2011, 32, 2748-2757.	2.2	82
94	Risk Profile and 3-Year Outcomes From the SYNTAX Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting Nested Registries. JACC: Cardiovascular Interventions, 2012, 5, 618-625.	2.9	82
95	Surgical Treatment of Active Native Aortic Valve Endocarditis With Allografts and Mechanical Prostheses. Annals of Thoracic Surgery, 2009, 88, 1814-1821.	1.3	80
96	Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients. American Heart Journal, 2017, 190, 54-63.	2.7	78
97	The SYNTAX score and its clinical implications. Heart, 2014, 100, 169-177.	2.9	75
98	Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization. Journal of the American College of Cardiology, 2020, 76, 1609-1621.	2.8	75
99	Impact of Peri-Procedural MyocardialÂInfarction on Outcomes AfterÂRevascularization. Journal of the American College of Cardiology, 2020, 76, 1622-1639.	2.8	73
100	The CABG SYNTAX Score - an angiographic tool to grade the complexity of coronary disease following coronary artery bypass graft surgery: from the SYNTAX Left Main Angiographic (SYNTAX-LE MANS) substudy. EuroIntervention, 2013, 8, 1277-1285.	3.2	71
101	Quality-of-Life After Everolimus-Eluting Stents or Bypass Surgery for Left-MainÂDisease. Journal of the American College of Cardiology, 2017, 70, 3113-3122.	2.8	69
102	Long-term follow-up of coronary artery bypass grafting in three-vessel disease using exclusively pedicled bilateral internal thoracic and right gastroepiploic arteries. Annals of Thoracic Surgery, 2004, 77, 794-799.	1.3	68
103	The clinical outcome after coronary bypass surgery: a 30-year follow-up study. European Heart Journal, 2008, 30, 453-458.	2.2	68
104	Brom's three-patch technique for repair of supravalvular aortic stenosis. Journal of Thoracic and Cardiovascular Surgery, 1999, 118, 252-258.	0.8	67
105	Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial. European Heart Journal, 2019, 40, 1930-1941.	2.2	65
106	Survival After Pathological Stage IA Nonsmall Cell Lung Cancer: Tumor Size Matters. Annals of Thoracic Surgery, 2005, 79, 1137-1141.	1.3	64
107	Transapical Versus Transfemoral Aortic Valve Implantation: A Multicenter Collaborative Study. Annals of Thoracic Surgery, 2014, 97, 22-28.	1.3	64
108	Widening clinical applications of the SYNTAX Score. Heart, 2014, 100, 276-287.	2.9	64

#	Article	IF	CITATIONS
109	Long-term survival after non–small cell lung cancer surgery: Development and validation of a prognostic model with a preoperative and postoperative mode. Journal of Thoracic and Cardiovascular Surgery, 2006, 132, 491-498.	0.8	63
110	Quality of Life After Surgery or DES in Patients With 3-Vessel or Left Main Disease. Journal of the American College of Cardiology, 2017, 69, 2039-2050.	2.8	63
111	2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement. Annals of Thoracic Surgery, 2012, 93, 1340-1395.	1.3	62
112	Short-Term and Long-Term Clinical Impact of Stent Thrombosis and Graft Occlusion in the SYNTAX Trial at 5 Years. Journal of the American College of Cardiology, 2013, 62, 2360-2369.	2.8	62
113	Prosthesis–Patient Mismatch After Transcatheter Aortic Valve Implantation With the Medtronic CoreValve System in Patients With Aortic Stenosis. American Journal of Cardiology, 2010, 106, 255-260.	1.6	61
114	Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial. EuroIntervention, 2016, 12, 861-872.	3.2	61
115	Bypass Surgery or Stenting for LeftÂMainÂCoronary Artery Disease in PatientsÂWith Diabetes. Journal of the American College of Cardiology, 2019, 73, 1616-1628.	2.8	60
116	The new EuroSCORE II does not improve prediction of mortality in high-risk patients undergoing cardiac surgery: a collaborative analysis of two European centres. European Journal of Cardio-thoracic Surgery, 2013, 44, 1006-1011.	1.4	59
117	Prediction of Costs and Length of Stay in Coronary Artery Bypass Grafting. Annals of Thoracic Surgery, 2014, 98, 1286-1293.	1.3	59
118	Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2018, 72, 754-765.	2.8	59
119	One-year outcomes of patients with severe aortic stenosis and an STS PROM of less than three percent in the SURTAVI trial. EuroIntervention, 2018, 14, 877-883.	3.2	59
120	Outcomes After Coronary Stenting or Bypass Surgery for Men and Women With Unprotected Left Main Disease. JACC: Cardiovascular Interventions, 2018, 11, 1234-1243.	2.9	58
121	Effect of Experience on Results of Transcatheter Aortic Valve Implantation Using a Medtronic CoreValve System. American Journal of Cardiology, 2011, 107, 1824-1829.	1.6	57
122	Do We Need Separate Risk Stratification Models for Hospital Mortality After Heart Valve Surgery?. Annals of Thoracic Surgery, 2008, 85, 921-930.	1.3	56
123	Inâ€hospital complications after transcatheter aortic valve implantation revisited according to the valve academic research consortium definitions. Catheterization and Cardiovascular Interventions, 2011, 78, 457-467.	1.7	55
124	Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease. JACC: Cardiovascular Interventions, 2020, 13, 375-387.	2.9	55
125	Prediction of 1-Year Mortality in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2013, 6, 737-745.	2.9	54
126	Early echocardiographic evaluation following percutaneous implantation with the self-expanding CoreValve ReValving System aortic valve bioprosthesis. EuroIntervention, 2008, 4, 351-357.	3.2	54

#	Article	IF	CITATIONS
127	A comparison of patient characteristics and 30-day mortality outcomes after transcatheter aortic valve implantation and surgical aortic valve replacement for the treatment of aortic stenosis: a two-centre study. EuroIntervention, 2009, 5, 580-588.	3.2	54
128	Three life-years gained from smoking cessation after coronary artery bypass surgery: A 30-year follow-up study. American Heart Journal, 2008, 156, 473-476.	2.7	53
129	Persistent Annual Permanent Pacemaker Implantation Rate After Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis. Annals of Thoracic Surgery, 2012, 94, 1143-1149.	1.3	53
130	Costs for Surgical Aortic Valve Replacement According to Preoperative Risk Categories. Annals of Thoracic Surgery, 2013, 96, 500-506.	1.3	52
131	The SURTAVI model: proposal for a pragmatic risk stratification for patients with severe aortic stenosis. EuroIntervention, 2012, 8, 258-266.	3.2	52
132	Transcatheter aortic valve implantation: 10-year anniversary. Part II: clinical implications. European Heart Journal, 2012, 33, 2399-2402.	2.2	51
133	Four-Year Outcome of OPCAB No-Touch With Total Arterial Y-Graft: Making the Best Treatment a Daily Practice. Annals of Thoracic Surgery, 2009, 88, 796-801.	1.3	50
134	Therapeutic decisions for patients with symptomatic severe aortic stenosis: room for improvement?. European Journal of Cardio-thoracic Surgery, 2009, 35, 953-957.	1.4	49
135	Economic outcomes of percutaneous coronary intervention with drugâ€eluting stents versus bypass surgery for patients with left main or threeâ€vessel coronary artery disease: Oneâ€year results from the SYNTAX trial. Catheterization and Cardiovascular Interventions, 2012, 79, 198-209.	1.7	48
136	Factors associated with perioperative complications and long-term results after pulmonary resection for primary carcinoma of the lung. European Journal of Cardio-thoracic Surgery, 2003, 23, 26-29.	1.4	47
137	Allografts for aortic valve or root replacement: insights from an 18-year single-center prospective follow-up studyâ~†. European Journal of Cardio-thoracic Surgery, 2007, 31, 851-859.	1.4	46
138	2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement. Catheterization and Cardiovascular Interventions, 2012, 79, 1023-1082.	1.7	46
139	Analysis of Stroke Occurring in the SYNTAX Trial Comparing Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention in the Treatment of Complex Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 344-354.	2.9	46
140	Outcomes Among Patients Undergoing Distal Left Main Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e007007.	3.9	45
141	Population characteristics, treatment assignment and survival of patients with aortic stenosis referred for percutaneous valve replacement. EuroIntervention, 2008, 4, 250-255.	3.2	45
142	Improving coronary artery bypass grafting: a systematic review and meta-analysis on the impact of adopting transit-time flow measurement. European Journal of Cardio-thoracic Surgery, 2019, 56, 654-663.	1.4	43
143	The 4th European Association for Cardio-Thoracic Surgery adult cardiac surgery database report. Interactive Cardiovascular and Thoracic Surgery, 2011, 12, 4-5.	1.1	42
144	Intraoperative transit-time flow measurement and high-frequency ultrasound assessment in coronary artery bypass grafting. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 1283-1292.e2.	0.8	41

#	Article	IF	CITATIONS
145	Impact of Optimal Medical Therapy on 10-Year Mortality After CoronaryÂRevascularization. Journal of the American College of Cardiology, 2021, 78, 27-38.	2.8	41
146	Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study. Circulation, 2021, 144, 96-109.	1.6	41
147	A systematic review of risk prediction in adult cardiac surgery: considerations for future model development. European Journal of Cardio-thoracic Surgery, 2013, 43, e121-e129.	1.4	40
148	The European Association for Cardio-Thoracic Surgery (EACTS) database: an introduction. European Journal of Cardio-thoracic Surgery, 2013, 44, e175-e180.	1.4	40
149	A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users. Genetics in Medicine, 2015, 17, 3-11.	2.4	40
150	Cause of death after transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2014, 83, E277-82.	1.7	39
151	Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery, 2017, 52, 206-217.	1.4	39
152	Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer. Annals of Thoracic Surgery, 2005, 80, 1021-1026.	1.3	38
153	Outcomes After Left Main Percutaneous Coronary Intervention Versus CoronaryÂArtery Bypass Grafting According to Lesion Site. JACC: Cardiovascular Interventions, 2018, 11, 1224-1233.	2.9	38
154	Long term follow up after surgery in congenitally corrected transposition of the great arteries with a right ventricle in the systemic circulation. Journal of Cardiothoracic Surgery, 2010, 5, 74.	1.1	37
155	Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles. European Heart Journal, 2015, 36, 1851-1877.	2.2	37
156	True percutaneous implantation of the CoreValve aortic valve prosthesis by the combined use of ultrasound guided vascular access, Prostar(R) XL and the TandemHeart(R). EuroIntervention, 2007, 2, 500-5.	3.2	37
157	Complexity of Coronary Vasculature Predicts Outcome of Surgery for Left Main Disease. Annals of Thoracic Surgery, 2009, 87, 1097-1105.	1.3	36
158	Angiographic outcomes following stenting or coronary artery bypass surgery of the left main coronary artery: fifteen-month outcomes from the synergy between PCI with TAXUS express and cardiac surgery left main angiographic substudy (SYNTAX-LE MANS). EuroIntervention, 2011, 7, 670-679.	3.2	36
159	A crucial factor in shared decision making: the team approach. Lancet, The, 2011, 377, 1836.	13.7	35
160	Pediatric Autograft Aortic Root Replacement: A Prospective Follow-Up Study. Annals of Thoracic Surgery, 2005, 80, 1628-1633.	1.3	34
161	Long-term follow-up and quality of life after closure of ventricular septal defect in adults. European Journal of Cardio-thoracic Surgery, 2007, 32, 215-219.	1.4	34
162	Natural History of Asymptomatic Severe Aortic Stenosis and the Association of Early Intervention With Outcomes. JAMA Cardiology, 2020, 5, 1102.	6.1	34

Arie Pieter Kappetein

#	Article	IF	CITATIONS
163	EACTS guidelines for the use of patient safety checklists. European Journal of Cardio-thoracic Surgery, 2012, 41, 993-1004.	1.4	33
164	Percutaneous coronary invervention versus coronary artery bypass grafting: A meta-analysis. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 831-838.e13.	0.8	33
165	Safety, effectiveness and haemodynamic performance of a new stented aortic valve bioprosthesisâ€. European Journal of Cardio-thoracic Surgery, 2017, 52, 425-431.	1.4	33
166	One-year outcomes associated with a novel stented bovine pericardial aortic bioprosthesis. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1368-1377.e5.	0.8	33
167	Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery forÂLeftÂMainÂDisease. Journal of the American College of Cardiology, 2019, 73, 1877-1886.	2.8	33
168	Prognostic implications of severe coronary calcification in patients undergoing coronary artery bypass surgery: An analysis of the SYNTAX Study. Catheterization and Cardiovascular Interventions, 2015, 85, 199-206.	1.7	32
169	10-Year Follow-Up After Revascularization in Elderly Patients With Complex Coronary Artery Disease. Journal of the American College of Cardiology, 2021, 77, 2761-2773.	2.8	32
170	Recognition, assessment and management of the mechanical complications of acute myocardial infarction. Heart, 2018, 104, 1216-1223.	2.9	30
171	Sex Differences in All-Cause Mortality in the Decade Following Complex CoronaryÂRevascularization. Journal of the American College of Cardiology, 2020, 76, 889-899.	2.8	30
172	Validation of the SYNTAX Revascularization Index to Quantify Reasonable Level of Incomplete Revascularization After Percutaneous Coronary Intervention. American Journal of Cardiology, 2015, 116, 174-186.	1.6	29
173	Do Differences in Repeat Revascularization Explain the Antianginal Benefits of Bypass Surgery Versus Percutaneous Coronary Intervention?. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 267-275.	2.2	28
174	Off-Pump Versus On-Pump Bypass Surgery for Left Main Coronary ArteryÂDisease. Journal of the American College of Cardiology, 2019, 74, 729-740.	2.8	28
175	Diagnosis and management of aortic valve stenosis in patients with heart failure. European Journal of Heart Failure, 2016, 18, 469-481.	7.1	27
176	EACTS clinical statement: guidance for the provision of adult cardiac surgery: Table 1:. European Journal of Cardio-thoracic Surgery, 2016, 50, 1006-1009.	1.4	27
177	Neurological Complications AfterÂTranscatheter Versus Surgical Aortic Valve Replacement in Intermediate-Risk Patients. Journal of the American College of Cardiology, 2018, 72, 2109-2119.	2.8	27
178	Impact of left ventricular ejection fraction on clinical outcomes after left main coronary artery revascularization: results from the randomized EXCEL trial. European Journal of Heart Failure, 2020, 22, 871-879.	7.1	27
179	Two cases of aneurysm of the anterior mitral valve leaflet associated with transcatheter aortic valve endocarditis: A mere coincidence?. Journal of Thoracic and Cardiovascular Surgery, 2010, 140, e36-e38.	0.8	26
180	Surgery in current therapy for infective endocarditis. Vascular Health and Risk Management, 2011, 7, 255.	2.3	26

#	Article	IF	CITATIONS
181	Differences in baseline characteristics, practice patterns and clinical outcomes in contemporary coronary artery bypass grafting in the United States and Europe: insights from the SYNTAX randomized trial and registry. European Journal of Cardio-thoracic Surgery, 2015, 47, 685-695.	1.4	26
182	B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease. Circulation, 2018, 138, 469-478.	1.6	25
183	Bilateral mammary artery vs. single mammary artery grafting: promising early results: but will the match finish with enough players?. European Heart Journal, 2010, 31, 2444-2446.	2.2	24
184	Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. European Heart Journal, 2021, 43, 56-67.	2.2	23
185	10-Year All-Cause Mortality Following Percutaneous or Surgical Revascularization inÂPatientsÂWithÂHeavyÂCalcification. JACC: Cardiovascular Interventions, 2022, 15, 193-204.	2.9	23
186	Sutureless versus Stented Bioprostheses for Aortic Valve Replacement: The Randomized PERSIST-AVR Study Design. Thoracic and Cardiovascular Surgeon, 2020, 68, 114-123.	1.0	22
187	Heart Team decision making and long-term outcomes for 1000 consecutive cases of coronary artery disease. Interactive Cardiovascular and Thoracic Surgery, 2019, 28, 206-213.	1.1	21
188	Five-year haemodynamic outcomes of the first-generation SAPIEN balloon-expandable transcatheter heart valve. EuroIntervention, 2016, 12, 775-782.	3.2	21
189	Cost-effectiveness of transcatheter valvular interventions: economic challenges. EuroIntervention, 2013, 9, S48-S54.	3.2	21
190	Conceptual model for early health technology assessment of current and novel heart valve interventions. Open Heart, 2016, 3, e000500.	2.3	20
191	Cost, quality, and value in coronary artery bypass grafting. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 2729-2735.e1.	0.8	19
192	Complete 2-Year Results Confirm Bayesian Analysis of the SURTAVI Trial. JACC: Cardiovascular Interventions, 2020, 13, 323-331.	2.9	19
193	Long-term survival after coronary bypass surgery with multiple versus single arterial grafts. European Journal of Cardio-thoracic Surgery, 2022, 61, 925-933.	1.4	19
194	The impact of a second arterial graft on 5-year outcomes after coronary artery bypass grafting in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery Trial and Registry. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 597-606.e2.	0.8	18
195	Influence of practice patterns on outcome among countries enrolled in the SYNTAX trial: 5-year results between percutaneous coronary intervention and coronary artery bypass graftingâ€. European Journal of Cardio-thoracic Surgery, 2017, 52, 445-453.	1.4	18
196	Outcomes following surgical revascularization with single versus bilateral internal thoracic arterial grafts in patients with left main coronary artery disease undergoing coronary artery bypass grafting: insights from the EXCEL trialâ€. European Journal of Cardio-thoracic Surgery, 2019, 55, 501-510.	1.4	18
197	Mortality 10 Years After Percutaneous or Surgical Revascularization in Patients With Total Coronary Artery Occlusions. Journal of the American College of Cardiology, 2021, 77, 529-540.	2.8	17
198	Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease. European Heart Journal, 2022, 43, 1334-1344.	2.2	17

#	Article	IF	CITATIONS
199	Frequency and pattern of de-novo three-vessel and left main coronary artery disease; insights from single center enrolment in the SYNTAX studyâ~†. European Journal of Cardio-thoracic Surgery, 2008, 34, 376-383.	1.4	16
200	The fallacy of indexed effective orifice area charts to predict prosthesis–patient mismatch after prosthesis implantation. European Heart Journal Cardiovascular Imaging, 2020, 21, 1116-1122.	1.2	16
201	Causes of death in intermediate-risk patients: The Randomized Surgical Replacement and Transcatheter Aortic Valve Implantation Trial. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 718-728.e3.	0.8	16
202	Incidence, correlates, and significance of abnormal cardiac enzyme rises in patients treated with surgical or percutaneous based revascularisation. International Journal of Cardiology, 2013, 168, 5287-5292.	1.7	15
203	Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective. Heart, 2015, 101, 1980-1988.	2.9	15
204	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Disease. New England Journal of Medicine, 2017, 376, 1087-1089.	27.0	15
205	Approaches to the Role of The Heart Team in Therapeutic Decision Making for Heart Valve Disease. Structural Heart, 2017, 1, 249-255.	0.6	15
206	Left Main Coronary Artery Disease Revascularization According to the SYNTAX Score. Circulation: Cardiovascular Interventions, 2019, 12, e008007.	3.9	15
207	Current decision making and short-term outcome in patients with degenerative aortic stenosis: the Pooled-RotterdAm-Milano-Toulouse In Collaboration Aortic Stenosis survey. EuroIntervention, 2016, 11, e1305-e1313.	3.2	15
208	Completely percutaneous transcatheter aortic valve implantation through transaxillary route: an evolving concept. EuroIntervention, 2012, 7, 1340-1342.	3.2	15
209	Transcatheter aortic valve replacement and vascular complications definitions. EuroIntervention, 2014, 9, 1317-1322.	3.2	15
210	The coronary artery bypass graft SYNTAX Score: final five-year outcomes from the SYNTAX-LE MANS left main angiographic substudy. EuroIntervention, 2013, 9, 1009-1010.	3.2	15
211	Virtual reality 3D echocardiography in the assessment of tricuspid valve function after surgical closure of ventricular septal defect. Cardiovascular Ultrasound, 2007, 5, 8.	1.6	14
212	Predicting prognosis in cardiac surgery: a prophecy?. European Journal of Cardio-thoracic Surgery, 2012, 41, 732-733.	1.4	14
213	Long-term outlook for transcatheter aortic valve replacement. Trends in Cardiovascular Medicine, 2018, 28, 174-183.	4.9	14
214	Intraoperative Real Time Threeâ€Dimensional Transesophageal Echocardiographic Measurement of Hemodynamic, Anatomic and Functional Changes after Aortic Valve Replacement. Echocardiography, 2009, 26, 96-99.	0.9	13
215	Subgroup Analyses in Trial Reports Comparing Percutaneous Coronary Intervention With Coronary Artery Bypass Surgery. JAMA - Journal of the American Medical Association, 2013, 310, 2097.	7.4	13
216	Standards defining a â€~Heart Valve Centre': ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint. European Journal of Cardio-thoracic Surgery, 2017, 52, 418-424.	1.4	13

#	Article	IF	CITATIONS
217	C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial. American Heart Journal, 2019, 210, 49-57.	2.7	13
218	Usefulness of microsimulation to translate valve performance into patient outcome: Patient prognosis after aortic valve replacement with the Carpentier–Edwards supra-annular valve. Journal of Thoracic and Cardiovascular Surgery, 2007, 134, 702-709.e1.	0.8	12
219	Validation of a prognostic model to predict survival after non-small-cell lung cancer surgery. European Journal of Cardio-thoracic Surgery, 2010, 38, 615-619.	1.4	12
220	Off-Pump or On-Pump Coronary-Artery Bypass Grafting. New England Journal of Medicine, 2012, 367, 577-578.	27.0	12
221	Considerations and Recommendations for the Introduction of Objective Performance Criteria for Transcatheter Aortic Heart Valve Device Approval. Circulation, 2016, 133, 2086-2093.	1.6	12
222	Revascularization Options. Heart Failure Clinics, 2016, 12, 135-139.	2.1	12
223	Comparison of Outcomes After Transcatheter vs Surgical Aortic Valve Replacement Among Patients at Intermediate Operative Risk With a History of Coronary Artery Bypass Graft Surgery. JAMA Cardiology, 2019, 4, 810.	6.1	12
224	Outcome after aortic valve replacement in young adults: is patient profile more important than prosthesis type?. Journal of Heart Valve Disease, 2006, 15, 479-87; discussion 487.	0.5	12
225	Editorial Comment: The role of EuroSCORE II in 21st century cardiac surgery practice. European Journal of Cardio-thoracic Surgery, 2013, 43, 32-33.	1.4	11
226	The Clinical Implications of Body Surface Area as a Poor Proxy for Cardiac Output. Structural Heart, 2021, 5, 582-587.	0.6	11
227	Clinical endpoints in transcatheter aortic valve implantation: a call to ARC for standardised definitions. EuroIntervention, 2009, 5, 29-31.	3.2	11
228	How to assess risks of valve surgery: quality, implementation and future of risk models. Heart, 2009, 95, 1958-1963.	2.9	10
229	Impact of non-respect of SYNTAX score II recommendation for surgery in patients with left main coronary artery disease treated by percutaneous coronary intervention: an EXCEL substudy. European Journal of Cardio-thoracic Surgery, 2019, 57, 676-683.	1.4	10
230	Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study. Clinical Research in Cardiology, 2021, 110, 1083-1095.	3.3	10
231	Impact of stent length and diameter on 10â€year mortality in the <scp>SYNTAXES</scp> trial. Catheterization and Cardiovascular Interventions, 2021, 98, E379-E387.	1.7	10
232	CABG, stents, or hybrid procedures for left main disease?. EuroIntervention, 2015, 11, V111-V114.	3.2	10
233	Is a bicuspid aortic valve a risk factor for adverse outcome after an autograft procedure?. Annals of Thoracic Surgery, 2004, 77, 1998-2003.	1.3	9
234	Does the type of biological valve affect patient outcome?. Interactive Cardiovascular and Thoracic Surgery, 2006, 5, 398-402.	1.1	9

#	Article	lF	CITATIONS
235	Cost-Effectiveness and Projected Survival of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement for High Risk Patients in a European Setting: A Dutch Analysis Based on the CoreValve High Risk Trial. Structural Heart, 2017, 1, 267-274.	0.6	9
236	Outcomes of left main revascularization in patients with acute coronary syndromes and stable ischemic heart disease: Analysis from the EXCEL trial. American Heart Journal, 2019, 214, 9-17.	2.7	9
237	Computed Tomography–Based Indexed Aortic Annulus Size to Predict Prosthesis-Patient Mismatch. Circulation: Cardiovascular Interventions, 2019, 12, e007396.	3.9	9
238	Adoption of Transcatheter Aortic Valve Implantation in Western Europe. Interventional Cardiology Review, 2011, 9, 37.	1.6	9
239	Patient selection for TAVI in 2014: is there a justification for treating low- or intermediate-risk patients? The surgeon's view. EuroIntervention, 2014, 10, U11-U15.	3.2	9
240	What is the evidence allowing us to state that transcatheter aortic valve replacement via the femoral artery is a more attractive option compared to transapical valve replacement?. EuroIntervention, 2011, 7, 903-904.	3.2	9
241	Surgical or transcatheter mitral valve intervention: complex disease requires complex decisions. EuroIntervention, 2014, 9, 1133-1135.	3.2	9
242	Survival of proximal third gastric carcinoma. , 1998, 68, 183-186.		8
243	Editorial commentIs there enough evidence that proves clinical equipoise between stenting and coronary surgery for patients with left main coronary artery disease?. European Journal of Cardio-thoracic Surgery, 2010, 38, 428-430.	1.4	8
244	Patient selection for transcatheter aortic valve replacement: what does the future hold?. Expert Review of Cardiovascular Therapy, 2012, 10, 679-681.	1.5	8
245	Antithrombotic therapy and bleeding events after aortic valve replacement with a novel bioprosthesis. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 66-75.e4.	0.8	8
246	Predicted patient outcome after aortic valve replacement with Medtronic Stentless Freestyle bioprostheses. Journal of Heart Valve Disease, 2007, 16, 423-8; discussion 429.	0.5	8
247	Multivessel coronary artery disease: quantifying how recent trials should influence clinical practice. Expert Review of Cardiovascular Therapy, 2013, 11, 903-918.	1.5	7
248	Revascularization Options. Cardiology Clinics, 2014, 32, 457-461.	2.2	7
249	Interpretation of results of pooled analysis of individual patient data – Authors' reply. Lancet, The, 2018, 392, 818.	13.7	7
250	Impact of lesion preparation strategies on outcomes of left main <scp>PCI</scp> : The <scp>EXCEL</scp> trial. Catheterization and Cardiovascular Interventions, 2021, 98, 24-32.	1.7	7
251	Considerations for an optimal definition of procedural myocardial infarction. European Heart Journal, 2020, 41, 1704-1705.	2.2	7
252	Mortality after multivessel revascularisation involving the proximal left anterior descending artery. Heart, 2022, 108, 1784-1791.	2.9	7

#	Article	IF	CITATIONS
253	Stentless bioprostheses have ideal haemodynamics, even in the small aortic root. International Journal of Cardiovascular Imaging, 2000, 16, 359-364.	0.6	6
254	Adapt or die. The imperative for a culture of innovation in cardio-thoracic surgical training. European Journal of Cardio-thoracic Surgery, 2007, 31, 959-959.	1.4	6
255	Non-cardiac surgery in patients with severe aortic stenosis: time to revise the guidelines?: Figure 1. European Heart Journal, 2014, 35, 2346-2348.	2.2	6
256	Aortic valve replacement in younger adults: a biological valve is not the logical choice. European Heart Journal, 2016, 37, 2668-2670.	2.2	6
257	A case-vignette based assessment of patient's perspective on coronary revascularization strategies, the OPINION study. Journal of Cardiology, 2018, 72, 149-154.	1.9	6
258	Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With PriorÂCerebrovascular Disease. JACC: Cardiovascular Interventions, 2018, 11, 2441-2450.	2.9	6
259	Life-long clinical outcome after the first myocardial revascularization procedures: 40-year follow-up after coronary artery bypass grafting and percutaneous coronary intervention in Rotterdam. Interactive Cardiovascular and Thoracic Surgery, 2019, 28, 852-859.	1.1	6
260	Impact of chronic obstructive pulmonary disease on prognosis after percutaneous coronary intervention and bypass surgery for left main coronary artery disease: an analysis from the EXCEL trial. European Journal of Cardio-thoracic Surgery, 2019, 55, 1144-1151.	1.4	6
261	Impact of Body Composition Indices on Ten-year Mortality After Revascularization of Complex Coronary Artery Disease (From the Syntax Extended Survival Trial). American Journal of Cardiology, 2021, 151, 30-38.	1.6	6
262	TAVI at institutions without cardiovascular surgery departments: why?. EuroIntervention, 2014, 10, 539-541.	3.2	6
263	Cost effectiveness of coronary revascularisation. EuroIntervention, 2010, 5, 763-767.	3.2	6
264	Transcatheter Lotus valve implantation in a regurgitant SAPIEN 3 valve. EuroIntervention, 2015, 11, 356-356.	3.2	6
265	Ten-year all-cause mortality according to smoking status in patients with severe coronary artery disease undergoing surgical or percutaneous revascularization. European Journal of Preventive Cardiology, 2022, 29, 312-320.	1.8	6
266	Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial. EuroIntervention, 2022, 17, 1477-1487.	3.2	6
267	CABG or PCI for revascularisation in patients with diabetes?. Lancet Diabetes and Endocrinology,the, 2013, 1, 266-268.	11.4	5
268	Arterial grafting and complete revascularization. Current Opinion in Cardiology, 2013, 28, 646-653.	1.8	5
269	Single-centre experience with mitral valve repair in asymptomatic patients with severe mitral valve regurgitationâ€. Interactive Cardiovascular and Thoracic Surgery, 2013, 16, 731-737.	1.1	5
270	Methodology manual for European Association for Cardio-Thoracic Surgery (EACTS) clinical guidelines. European Journal of Cardio-thoracic Surgery, 2015, 48, ezv309.	1.4	5

#	Article	IF	CITATIONS
271	Transcatheter Lotus Valve Implantation inÂa Stenotic Mitral Valve. JACC: Cardiovascular Interventions, 2016, 9, e215-e217.	2.9	5
272	Doing better in more complex patients: leading the way for QUIP. European Journal of Cardio-thoracic Surgery, 2016, 49, 397-398.	1.4	5
273	New Anticoagulants in Cardiac Surgery. Interventional Cardiology Review, 2011, 6, 71.	1.6	5
274	Failing surgical bioprosthesis in aortic and mitral position. EuroIntervention, 2013, 9, S77-S83.	3.2	5
275	Carriage of Reduced-Function <i>CYP2C19</i> Allele Among Patients Treated With Clopidogrel. JAMA - Journal of the American Medical Association, 2011, 305, 467.	7.4	4
276	Drug-eluting stent implantation for coronary artery disease: current stents and a comparison with bypass surgery. Current Opinion in Pharmacology, 2012, 12, 147-154.	3.5	4
277	Outcomes After Left Main Coronary Artery Revascularization by Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting According to Smoking Status. American Journal of Cardiology, 2020, 127, 16-24.	1.6	4
278	Ten-year all-cause death following percutaneous or surgical revascularization in patients with prior cerebrovascular disease: insights from the SYNTAX Extended Survival study. Clinical Research in Cardiology, 2021, 110, 1543-1553.	3.3	4
279	Transit time flow measurement of coronary bypass grafts before and after protamine administration. Journal of Cardiothoracic Surgery, 2021, 16, 195.	1.1	4
280	Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease. Clinical Research in Cardiology, 2021, 110, 1680-1691.	3.3	4
281	Transcatheter aortic valve implantation after PARTNER: what is up next?. EuroIntervention, 2010, 6, 560-561.	3.2	4
282	Value of Keeping Records of Mortality. The European Journal of Surgery, 2002, 168, 436-440.	0.9	3
283	Optimum management of elderly patients with calcified aortic stenosis. Expert Review of Cardiovascular Therapy, 2008, 6, 491-501.	1.5	3
284	Transapical implantation of a self-expanding aortic valve bioprosthesis — animal feasibility studyâ~†. European Journal of Cardio-thoracic Surgery, 2009, 36, 813-817.	1.4	3
285	Towards excellence in revascularization for left main coronary artery disease. Current Opinion in Cardiology, 2012, 27, 604-610.	1.8	3
286	Appropriate Coronary Artery Bypass Grafting Use in the Percutaneous Coronary Intervention Era: Are We Finally Making Progress?. Seminars in Thoracic and Cardiovascular Surgery, 2012, 24, 241-243.	0.6	3
287	The bright future of cardiothoracic and vascular surgery: the role of EACTSâ€. European Journal of Cardio-thoracic Surgery, 2013, 43, 211-214.	1.4	3
288	Minimally invasive transaortic transcatheter aortic valve implantation of the CoreValve prosthesis: the direct aortic approach through a mini-sternotomy. Multimedia Manual of Cardiothoracic Surgery: MMCTS / European Association for Cardio-Thoracic Surgery, 2013, 2013, mmt018-mmt018.	0.1	3

#	Article	IF	CITATIONS
289	Essential information on surgical heart valve characteristics for optimal valve prosthesis selection: Expert consensus document from the European Association for Cardio-Thoracic Surgery (EACTS)–The Society of Thoracic Surgeons (STS)–American Association for Thoracic Surgery (AATS) Valve Labelling Task Force. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 545-558.	0.8	3
290	Essential Information on Surgical Heart Valve Characteristics for Optimal Valve Prosthesis Selection: Expert Consensus Document From the European Association for Cardio-Thoracic Surgery (EACTS)–The Society of Thoracic Surgeons (STS)–American Association for Thoracic Surgery (AATS) Valve Labelling Task Force. Annals of Thoracic Surgery, 2021, 111, 314-326.	1.3	3
291	Impact of the CABG SYNTAX score on all-cause death at 10 years: a SYNTAX Extended Survival (SYNTAXES) substudy. EuroIntervention, 2021, 17, 75-77.	3.2	3
292	How should I treat a patient with severe and symptomatic aortic stenosis who is rejected for surgical and transfemoral valve replacement and in whom a transapical implantation was aborted?. EuroIntervention, 2008, 4, 292-296.	3.2	3
293	Methodologic issues regarding background mortality in observational studies. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 1289-1290.	0.8	2
294	Details in a meta-analysis comparing mitral valve repair to replacement for ischemic regurgitation. European Journal of Cardio-thoracic Surgery, 2011, 41, 236-7; author reply 237-8.	1.4	2
295	GuÃade práctica clÃnica sobre el tratamiento de las valvulopatÃas (versión 2012). Revista Espanola De Cardiologia, 2013, 66, 131.e1-131.e42.	1.2	2
296	Long-Term Survival of Young Patients With Coronary Artery Disease Is Best Realized Through Surgical Revascularization With Mammary Arteries. Journal of the American College of Cardiology, 2013, 61, 2312-2313.	2.8	2
297	Age Cutoffs for Bioprosthetic vs Mechanical Aortic Valve Replacement. JAMA - Journal of the American Medical Association, 2015, 313, 522.	7.4	2
298	50th Anniversary Landmark Commentary on Carpentier A, Guermonprez JL, Deloche A, Frechette C, DuBost C. The aorta-to-coronary radial artery bypass graft. Ann Thorac Surg 1973;16:111–21. Annals of Thoracic Surgery, 2015, 99, 1500.	1.3	2
299	Aortic valve and aortic diseases: update on current treatment options. Minimally Invasive Therapy and Allied Technologies, 2015, 24, 253-254.	1.2	2
300	Geographical variations in left main coronary artery revascularisation: a prespecified analysis of the EXCEL trial. EuroIntervention, 2022, 17, 1081-1090.	3.2	2
301	Echocardiographic Imaging of Stentless Aortic Valve Prostheses. Echocardiography, 2000, 17, 625-629.	0.9	1
302	Management of elderly patients with aortic valve disease. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 600-601.	3.3	1
303	Nonrandomized Data on Drug-Eluting Stents Compared With Coronary Bypass Surgery. Journal of the American College of Cardiology, 2011, 57, 2457-2458.	2.8	1
304	Impact of methodology and assumptions inÂa cost-effectiveness analysis on transcatheter aortic valve replacement. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 607.	0.8	1
305	Response to Letter Regarding Article, "Quantification of Incomplete Revascularization and Its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial: Validation of the Residual SYNTAX Score― Circulation, 2014. 129. e355-6.	1.6	1
306	Role of Percutaneous Coronary Intervention in the Treatment of Left Main Coronary Artery Disease. Seminars in Thoracic and Cardiovascular Surgery, 2014, 26, 187-191.	0.6	1

#	Article	IF	CITATIONS
307	Reflect on DEFLECT. European Heart Journal, 2015, 36, 2034-2035.	2.2	1
308	What the cardiothoracic surgeon wants to know from the radiologist: from X-ray reporting to imaging consultancy and Heart Team membership. Pediatric Radiology, 2015, 45, 27-31.	2.0	1
309	Transcatheter Lotus Valve Implantation inÂa Degenerated Carpentier-Edwards Bioprosthesis. JACC: Cardiovascular Interventions, 2015, 8, e27-e28.	2.9	1
310	Bilateral internal thoracic artery use: will another retrospective study ever strengthen the prospect?. European Journal of Cardio-thoracic Surgery, 2015, 47, 709-711.	1.4	1
311	Von Willebrand factor multimers during transcatheter aortic valve replacement—an additional clue for detecting post-procedural aortic regurgitation?. Journal of Thoracic Disease, 2016, 8, E1697-E1700.	1.4	1
312	The Clinical Reality With UncertainÂConsequences of BiologicalÂValve Thrombosis â^—. Journal of the American College of Cardiology, 2016, 68, 2070-2072.	2.8	1
313	Transcatheter Mitral Valve Implantation in a Patient With an Aortic Mechanical Valve. JACC: Cardiovascular Interventions, 2016, 9, e31-e33.	2.9	1
314	Coronary artery disease: a dam in the river for ranolazine. Lancet, The, 2016, 387, 100-102.	13.7	1
315	Effectiveness in a Real-World ObservationÂConfirms Efficacy of Controlled Clinical Trials â^—. Journal of the American College of Cardiology, 2017, 70, 451-452.	2.8	1
316	Reply to Gasz. European Journal of Cardio-thoracic Surgery, 2018, 54, 196-197.	1.4	1
317	Long-Term Survival After SurgicalÂAorticÂValve Replacement. Journal of the American College of Cardiology, 2019, 74, 34-35.	2.8	1
318	Outcomes of patients with and without baseline lipid-lowering therapy undergoing revascularization for left main coronary artery disease. Coronary Artery Disease, 2019, 30, 143-149.	0.7	1
319	Impact of renin-angiotensin system inhibitors after revascularization of patients with left main coronary artery disease. Coronary Artery Disease, 2021, Publish Ahead of Print, 37-44.	0.7	1
320	Impact of major infections on 10-year mortality after revascularization in patients with complex coronary artery disease. International Journal of Cardiology, 2021, 341, 9-12.	1.7	1
321	Computed Tomography Annular Dimensions: A Novel Method to Compare Prosthetic Valve Hemodynamics. Annals of Thoracic Surgery, 2020, 110, 1502-1510.	1.3	1
322	Left main stenting: do we need another study?. EuroIntervention, 2010, 6, J118-J122.	3.2	1
323	The heart team in acute cardiac care. , 2015, , .		1
324	Does an occluded RCA affect prognosis in patients undergoing PCI or CABG for left main coronary artery disease? Analysis from the EXCEL trial. EuroIntervention, 2019, 15, e531-e538.	3.2	1

#	Article	IF	CITATIONS
325	Emergency Surgery Due to Haematoma in a Case of Left Atrial Myxoma. Heart Lung and Circulation, 2006, 15, 191-193.	0.4	0
326	Invited Commentary. Annals of Thoracic Surgery, 2008, 86, 219.	1.3	0
327	Letter by Van de Werf et al Regarding Article, "Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians― Stroke, 2012, 43, e46-7; author reply e49.	2.0	0
328	What do we know about the natural history of severe symptomatic aortic valve stenosis?. Interventional Cardiology, 2012, 4, 203-210.	0.0	0
329	Invited Commentary. Annals of Thoracic Surgery, 2012, 93, 530.	1.3	0
330	Invited Commentary. Annals of Thoracic Surgery, 2014, 97, 528-529.	1.3	0
331	Reply to Hernández-Vaqueroet al European Journal of Cardio-thoracic Surgery, 2015, 48, 177.2-178.	1.4	0
332	Coronary artery bypass grafting in diabetic patients: do not bypass the pump!. European Journal of Cardio-thoracic Surgery, 2016, 49, 418-419.	1.4	0
333	Outpatient Versus Inpatient Percutaneous Coronary Intervention in Patients With Left Main Disease (from the EXCEL Trial). American Journal of Cardiology, 2021, 143, 21-28.	1.6	0
334	White blood cell count and clinical outcomes after left main coronary artery revascularization. Coronary Artery Disease, 2021, Publish Ahead of Print, 45-51.	0.7	0
335	Determinants of long-term outcome following bypass surgery ., 2012, , 422-427.		Ο
336	Measuring risk in valvular interventions: from low risk to futility. EuroIntervention, 2015, 14, W23-W25.	3.2	0
337	Mechanical Complications of Acute Myocardial Infarction. , 2018, , 341-357.		0
338	Endoscopic vs Open Vein Harvest in Drug-Eluting Stents or Bypass Surgery for Left Main Disease Trial. Annals of Thoracic Surgery, 2022, , .	1.3	0